SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

201883 citationsJournal Article

Authors

Our findings support <i>SLC46A3</i> as a potential patient selection biomarker with immediate relevance to clinical trials involving these ADCs.

Good health and well-being

Published in: Clinical Cancer Research

Volume 24, Issue 24, pp. 6570-6582

Field-Weighted Citation Impact: 5.71